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Abstract
Background: Current staging systems have limited ability to adjust optimal therapy in advanced nasopharyngeal
carcinoma (NPC). This study aimed to delineate the correlation between tumor volume, treatment outcome and
chemotherapy cycles in advanced NPC.
Methods: A retrospective review of 110 patients with stage III-IV NPC was performed. All patients were treated first
with neoadjuvant chemotherapy, then concurrent chemoradiation, and followed by adjuvant chemotherapy as
being the definitive therapy. Gross tumor volume of primary tumor plus retropharyngeal nodes (GTVprn) was
calculated to be an index of treatment outcome.
Results: GTVprn had a close relationship with survival and recurrence in advanced NPC. Large GTVprn (≧13 ml)
was associated with a significantly poorer local control, lower distant metastasis-free rate, and poorer survival. In
patients with GTVprn ≧ 13 ml, overall survival was better after ≧4 cycles of chemotherapy than after less than 4
cycles.
Conclusions: The incorporation of GTVprn can provide more information to adjust treatment strategy.
Background
Nasopharyngeal carcinoma (NPC) is a unique malignant
head and neck cancer with a specific behavior. It is
rarely reported in the West but occurs at high frequency
in Southern China, Hong Kong, Taiwan, Singapore, and
Malaysia [1]. Radiotherapy has long been the standard
treatment for patients with NPC because of its anatomic
location and relative radiosensitivity. Based on the
American Joint Committee on Cancer (AJCC) staging
system in 1997, and the 5-year overall survival rates for
tumor stages I, II, III, and IV were 95-70%, 83-65%, 76-
54%, and 56-29%, respectively [2-6]. Although NPC is
markedly radiosensitive, a high rate of treatment failure
is observed in patients with advanced NPC especially
distant failure. Combination chemotherapy plus radio-
therapy has been widely accepted as the treatment mod-
ality for advanced NPC; however, treatment strategies
for this disease have yet to be optimized [7-9].
T h ea c c u r a t ep r e d i c t i o no f prognosis and failure is
crucial for optimizing therapy. In general, the 1997
AJCC staging system is the most widely used staging
system for NPC [2]. However, the current TNM staging
system is based on anatomic location and cranial nerve
involvement that still has limitations. In addition to well
established prognostic facto r ss u c ha st u m o rs t a g e ,h i s -
topathologic type, and cranial nerve involvement, pri-
mary tumor volume has been recognized as a promising
prognostic indicator in the treatment of NPC [10-13].
Since use of tumor volume could improve the ability of
the current staging system to predict outcome, this
study aimed to delineate the correlation between tumor
volume, treatment outcome and chemotherapy cycles in
NPC treated with multimodality therapy.
Methods
Patients
For this retrospective analysis, the treatment records of
142 patients with stage III-IV NPC (AJCC system) [2]
from August 2000 to February 2007 in an institution
were reviewed. Thirty-two patients were excluded
because of distant metastasis present at initial diagnosis,
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nous second primary tumor. The histological diagnosis
of NPC was made by experienced pathologists. None of
the patients received prior treatment for their cancer.
All patients were informed about the treatment of
neoadjuvant chemotherapy then concurrent chemoradia-
tion (CCRT) and followed by adjuvant chemotherapy as
being the definitive therapy for advanced disease, includ-
ing the potential benefits and possible side effects. All
patients were treated by multidisciplinary teams includ-
ing a head and neck surgery team, radiation oncologists,
medical oncologists and dieticians.
Tumor volume measurement
All patients in this study underwent pre-treatment, con-
trast-enhanced CT scan that were done along the axial
scan plain parallel to the infraorbital-meatal line extend-
ing from the skull base to the top of manubrium using
3-5 mm sections. Direct coronal scans also were taken
to provide auxiliary information. One hundred milli-
meters of contrast medium were administrated with an
injection rate between 1 mL per second and 2.5 mL per
second after an initial 5-mL dose. Gross tumor volume
of primary tumor plus retropharyngeal nodes (GTVprn)
was included (depending on the imaging system) in the
tumor volume measurement. First, manual tracing was
performed using a graphic user interface, and area inside
the outline was automatically labeled and calculated.
The volume was calculated by multiplying the sum of
all areas by the slice thickness (image reconstruction
interval). All images were evaluated by two clinicians at
least. A radiologist who specialized in head and neck
cancer participated when the outline of tumor margin
was unclear.
Radiotherapy
An intensity-modulated radiation therapy (IMRT) tech-
nique and inverse planning system (PLATO, Nucleotron
Inc, Veenendaal, Netherlands) were used for treatment
delivery. The radiation field encompassed the primary
tumor bed and neck lymph nodes. The prescribed dose
of external beam treatment was 72 Gy to the gross
tumor and positive neck nodes, 63 Gy to the clinical tar-
get volume, and 50-60 Gy to the clinically negative neck.
Doses were delivered at 1.8 Gy/day for five consecutive
days by a linear accelerator with patients lying supine
with a mask. After 1-2 weeks of completing the external
beam radiotherapy, an intracavitary brachytherapy boost
(3.5 Gy to the submucosa 0.5 cm in 3 fractions) was
prescribed if residual tumor was suspected. The intraca-
vitary brachytherapy boost was conducted using high-
dose-rate (HDR) afterloader unit (microSelectron-HDR,
Nucleotron Inc, Veenendaal, Netherlands) containing an
iridium-192 source.
Chemotherapy
All consenting patients were eligible for chemotherapy if
they met the following criteria: ECOG performance sta-
tus ≤2, serum creatinine level <1.5 mg/dL, absolute neu-
trophil count ≥ 2000 cells/μL, and platelet count
>10,000/μL. The chemotherapy protocol consisted of 6
monthly cycles of cisplatin (100 mg/m
2/day) on Day 1
followed by 5-FU (1000 mg/m
2/day) continuously
infused for 5 consecutive days, in the presence of ade-
quate hydration and anti-emetic drugs.
Dose modification
Toxicity was evaluated using the common toxicity cri-
teria of the National Cancer Institute. Both cisplatin and
5-FU were withheld if the absolute neutrophil count was
<1500 cells/μL or if the platelet count was <75,000 cells/
μL. Both agents were given at 70% of the initial dose if
the neutrophil count was 1500-2000 cells/μLo ri ft h e
platelet count was 75,000-100,000 cells/μL. Radiotherapy
was withheld only if the neutrophil count was <1000
cells/μL or if the platelet count was <50,000 cells/μL.
For grades 3 and 4 oropharyngeal mucositis or diarrhea,
5-FU was withheld until the symptoms improved. It was
then restarted at 70% of the initial dose. For grades 3
and 4 renal toxicity, cisplatin was withheld until the
creatinine was <1.5 mg/dL. It was administered at 70%
of the initial dose thereafter.
Patient evaluation
Survival was calculated from the date of diagnosis to the
most recent follow-up or to the date of recurrence or
death. The pattern of failure was defined according to
the first site of failure: local failure defined as recurrence
of the primary tumor or metastasis to regional lymph
nodes; and distant failure indicating metastasis to any
site beyond the primary tumor and regional lymph
nodes. After recurrence or metastasis, patients were
given salvage therapy as determined by their physicians.
Statistical analysis
Different groups were compared with respect to base-
line characteristics, with the t- t e s tu s e df o rc o n t i n u o u s
variables and the chi-square test for categorical vari-
ables. The Kaplan-Meier method was used for survival
analysis [14]. The difference between survival curves was
determined using the log-rank test [15]. Multivariate
analysis to identify significant prognostic factors was
accomplished by Cox regression model. The receiver
operating characteristic (ROC) curve analysis was
applied to evaluate different cut-off point of tumor size
in order to find the appropriate size for clinical applica-
tion. SPSS 12.0 software (SPSS Inc, Chicago, IL, USA)
was used for analysis of all data. Statistical significance
was accepted as a p value of less than 0.05.
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Patient baseline characteristics are presented in Table 1.
Median patient follow-up at the commencement of the
analysis was 38 months (range 4-107). All patients
received the radiation. After extern beam radiotherapy,
13 of the 110 patients received an intracavitary bra-
chytherapy boost (3.5 Gy to the submucosa 0.5 cm in 3
fractions) because residual tumor was suspected. Median
cumulative radiation dose delivered over the study dura-
tion was 7200 cGy (range 6120-8250 cGy). For the rate
of compliance with chemotherapy treatment, the patient
received ≧ 4 and < 4 cycles of chemotherapy were 42%
and 58%, respectively. During follow up, 7 patients had
recurrence at the primary site, 23 patients had distant
metastasis, and 5 patients combined recurrence with
metastasis. The metastasis sites were the bone, lung, and
liver. The 3-year overall survival, disease-free survival,
local control, and distant metastasis-free rates in all
patients were 67%, 66%, 80%, and 66%, respectively.
Table 2 shows the T stage distribution and GTVprn
for each stage. The median GTVprn of stage III to IV
were 14.1 and 25.5 ml and corresponding ranges were
1.3-130.7 and 2.2-166.6 ml. The optimal GTVprn to
find the appropriate size for clinical application was 13
ml. For GTVprn analysis, the 3-year overall survival, dis-
ease-free survival, local control, and distant metastasis-
free rate in subgroups with GTVprn <13 ml and ≧ 13
ml were 92%/54%, 86%/25%, 95%/63%, and 88%/51%,
respectively. Large GTVprn (≧13 ml) was associated
with a significantly poorer local control, lower distant
metastasis-free rate, and poorer survival (Figure 1).
Besides, larger GTVprn (≧18 ml) was found to be corre-
lation with N stage which was a significant prognostic
factor on univariate analysis in distant metastasis free
rate. Analysis of the subgroup with GTVprn ≧ 13 ml
revealed better overall survival after ≧4c y c l e so fc h e -
motherapy than after less than 4 cycles (Figure 2).
Table 1 Patient Characteristics
Patient characteristic No. of patients (%)
All 110 (100)
Age
Median 52
Range 26–73
Gender
Male 71 (64.5)
Female 39 (35.5)
Histology
WHO type I 3 (2.7)
WHO type II 84 (76.4)
WHO type III 23 (20.9)
Performance status (ECOG)
0 103 (93.6)
1 4 (3.6)
2 3 (2.7)
AJCC 1997 T stage
1 20 (18.2)
2 35 (31.8)
3 23 (20.9)
4 32 (29.1)
AJCC 1997 N stage
0 2 (1.8)
1 3 (2.7)
2 75 (68.2)
3 30 (27.3)
AJCC 1997 Stage group
III 61 (55.5)
IV 49 (44.5)
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group;
AJCC, American Joint Committee on Cancer.
Table 2 T Stage and GTVprn
GTVprn (ml) Patients (%)
T stage Median Range GTVprn < 13 cm GTVprn ≥ 13 cm
T1 (n = 20) 4.60 1.3–11.4 20 (100) 0 (0)
T2 (n = 35) 15.3 2.3–37.2 17 (49) 18 (51)
T3 (n = 23) 21.3 3.6–130.7 14 (61) 9 (39)
T4 (n = 32) 31.9 6.7–166.6 12 (38) 20 (62)
GTVprn, gross tumor volume of primary tumor plus retropharyngeal nodes
Figure 1 Cumulative survival rates were stratified by primary
tumor volume. The 3-year overall survival in subgroups with
GTVprn <13 ml and ≧ 13 ml were 92% and 54%. Large GTVprn (≧
13 ml) was associated with a significantly poorer survival (p < 0.05).
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local control, and distant metastasis-free rates were
70%/24%, 63%/30%, 78%/76%, and 65%/42%, respec-
tively. A Cox proportional hazard regression model was
constructed to calculate the relative risks and confidence
intervals for different prognostic factors after controlling
for age and gender. The results are summarized in
T a b l e3 .O n l yG T V p r nw a sf o u n dt ob ea ni n d e p e n d e n t
factor. Survival analysis demonstrated a significant dif-
ference in overall survival with larger tumor volume
(risk ratio, 2.92; p = 0.02).
Discussion
The accurate prediction of prognosis and failure is crucial
for optimizing therapy. We addressed the question of
whether the AJCC staging system is adequate for predict-
ing the prognosis of patients with NPC. NPC is often
highly infiltrated and heterogeneous in all disease stages.
Recently, tumor volume has been evaluated as a predictor
because of the relationship of large volume with adverse
biologic factors, including clonogen number, hypoxia, and
radioresistance [11]. Several studies had demonstrated pri-
mary tumor volume could improve the current staging
system [10-13]. Chua et al. found that primary tumor
volume is an independent prognostic factor of local con-
trol and apparently more predictive than Ho’sTs t a g e
classification [12]. Chen et al. also demonstrated that pri-
mary tumor volume predicted survival of patients with
NPC with more accuracy than the AJCC staging system
[10]. This indicates the limitation of the current TNM sta-
ging system based on anatomic location in separation of
tumor bulk. Base on previous study, primary tumor
volume was found to be a significant prognosis factor for
treatment outcome and significantly correlated with T
stage [13]. In the current study, additional testing was per-
formed in an attempt to define the critical volume in the
advanced NPC. We used a cut off value of 13 ml to divide
patients into different prognostic groups. GTVprn ≧ 13 ml
was associated with a significantly poorer local control,
lower distant metastasis-free rate, and poorer survival.
Since most of our patients had stage N2 and N3 tumors,
we tried to determine whether GTVprn was correlated
with N stage. However, GTVprn would be increased to 18
ml which could be correlated with N stage. Because the
cut-off value of 13 ml could be used to predict and adjust
treatment strategy. These results led us to hypothesize
that GTVprn can refine the staging system and to specu-
late that micrometastases may sometimes occur before
neck lymph node involvement is apparent.
Distant metastasis is an important concern that can
influence survival. The reported frequency of distant
metastases in patients with locally advanced NPC was
greater than 30% with radiotherapy alone [7]. An
autopsy series had shown a high rate of distant metas-
tases (38-87%) involving virtually every organ [16].
Figure 2 Analysis of the subgroup with GTVprn ≧ 13 ml
revealed better overall survival after ≧ 4 cycles of
chemotherapy than after less than 4 cycles. (p < 0.05).
Table 3 Cox Proportional Hazard Model Analysis
Variables Overall
survival
(RR, 95% CI)
p Disease-specific
survival
(RR, 95% CI))
p Disease-free
survival
(RR, 95% CI)
p Loco-regional
control
(RR, 95% CI)
p Distant
metastasis-
free survival
(RR, 95% CI)
p
T1-2 vs. T3-4 1.29, 0.56-2.98 0.56 1.42, 0.41-4.86 0.58 0.85, 0.34-2.16 0.73 1.44, 0.27-7.64 0.67 1.00, 0.36-2.81 1.00
N0-2 vs. N3 2.47, 0.48-12.71 0.28 1.86, 0.15-23.26 0.63 2.85, 0.53-15.18 0.22 39.06, 1.55-983.27 0.03 2.77, 0.54-14.07 0.22
Cranial nerve
involvement
0.71, 0.26-1.95 0.51 0.73, 0.17-3.13 0.67 0.65, 0.18-2.28 0.50 0.11, 0.006-2.10 0.14 0.95, 0.26-3.46 0.94
Supraclavicular
nodes
0.74, 0.15-3.74 0.71 0.78, 0.06-9.59 0.85 0.45, 0.08-2.50 0.36 0.02, 0.001-0.87 0.04 0.68, 0.13-3.43 0.64
GTVprn (13 ml) 2.92, 1.22-6.98 0.02 4.10, 1.06-15.97 0.04 4.81, 1.73-13.36 < 0.01 16.83, 1.48-190.78 0.02 2.50, 0.84-7.43 0.10
RR, risk ratio; 95% CI, 95% confidence interval; GTVprn, gross tumor volume of primary tumor plus retropharyngeal nodes
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tion in an attempt to reduce the incidence of distant
metastasis. In this study, failure pattern analysis revealed
that the number of distant metastasis sites was greater
than the number of local recurrence sites. The 3-year
distant metastasis-free rate of 66% demonstrated that
distant metastasis was still the main challenge in
advanced NPC. In addition to delineate the cut off
volume into different prognostic groups, we also ana-
lyzed the prognosis of subgroups with different condi-
tions. We found that the subgroup with GTVprn ≧ 13
ml revealed longer survival after ≧ 4 cycles of che-
motherapy than after less than 4 cycles. These results
may hint the need for adequate systemic cycle regimes
to eradicate micrometastases and improve survival.
However, it is important to note that half of patients
required treatment modification during chemotherapy
or refused further treatment. More effective and safer
drugs should be considered for integration into multi-
modal treatment strategies.
Although incorporation of primary tumor volume could
improve the accuracy of the current staging system, it
still has some problems. One consideration is how tumor
volume is quantitatively determined. Clinical care
requires a classification system that reflects the current
state of scientific knowledge and can guide clinical deci-
sion-making. NPC tumor volume measurement is a com-
plicated procedure and the results may be affected by
imaging modalities (CT or MR imaging), measuring pro-
tocols, and measurement techniques [17]. Rasch et al.
indicated that MRI-derived tumor volume is smaller and
has less interobserver variation than CT-derived tumor
volume [18]. However, CT cannot be neglected because
the geometric accuracy of the patient contour is poorer
in MRI and lacks electron density information [10,19]. In
addition, measurement of tumor volume is still time-con-
suming, labourintensive, and not widely available. Tumor
volume definition and measuring protocols should be
standardized in clinical practice. Lee et al. had tried to
use simple measurement to evaluate of primary tumor
volume and seemed feasible [13]. Otherwise, although
large tumor volume was more commonly observed in the
higher stages, there were large variation tumor volume
and much overlapping among different stages [10-12]. Its
means similar values of tumor volume could have differ-
ent treatment response. Other factors such as tumor
extension, intrinsic resistance, or hypoxia should be con-
sidered for integration into the staging system.
Conclusions
Since this is a retrospective study, a number of factors
in terms of patient and tumor characteristics could not
be controlled and may have biased the results. Never-
theless, it appears that incorporation of tumor volume
can further refine the staging system and adjust treat-
ment strategy. For patients with large GTVprn (≧ 13
ml), the use of more effective and safer drugs with ade-
quate systemic cycles is suggested.
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